Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1012915 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Hunter L Colegrove und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Fanconi Anemia, Mouth Neoplasms, Genetic Therapy. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Fanconi Cancer Foundation, National Cancer Institute.
Abstract (Originalsprache)
Fanconi Anemia (FA) is a heritable syndrome characterized by DNA damage repair deficits, frequent malformations and a significantly elevated risk of bone marrow failure, leukemia, and mucosal head and neck squamous cell carcinomas (HNSCC). Hematopoietic stem cell gene therapy can prevent marrow failure and lower leukemia risk, but mucosal gene therapy to lower HNSCC risk remains untested. Major knowledge gaps include an incomplete understanding of how rapidly gene-corrected cellular lineages could spread through the oral epithelium, and which delivery parameters are critical for ensuring efficient gene correction. To answer these questions, we extended an agent-based model of the oral epithelium to include the delivery of gene correction in situ to FA cells and determine the competitive dynamics between cellular lineages with and without gene correction. We found that only gene-corrected lineages with substantial proliferative advantages (probability of resisting displacement out of the basal layer ≥ 0 . 1 ) could spread on clinically relevant timelines, and that these lineages were initially at high risk of loss in the generations following correction. Delivering gene correction to many cells minimizes the risk of loss, while delivery to many distinct locations within a tissue maximizes the rate of spread. To determine the impact of mucosal gene therapy in preventing the clonal expansion of pre-cancerous mutations, we compared the expected burden of TP53 mutations in simulated tissue sections with and without gene correction. We found that when FA cells have elevated genome instability or a TP53 -dependent proliferative advantage, gene correction can substantially reduce the accumulation of pro-tumorigenic mutations. This model illustrates the power of computational frameworks to identify critical determinants of therapeutic success to enable experimental optimization and support novel and effective gene therapy applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America.
- Department of Bioengineering, University of Washington, Seattle, Washington, United States of America.
- Herbold Computational Biology Program, Fred Hutch Cancer Center, Seattle, Washington, United States of America.
ORCID-Profile: Hunter L Colegrove, Raymond J Monnat, Alison F Feder
Förderung
- NCI NIH HHS
- Fanconi Cancer Foundation
- National Cancer Institute
Zitieren
APA
Colegrove, H. L., Monnat, R. J., & Feder, A. F. (2025). Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1012915
Vancouver
Colegrove HL, Monnat RJ, Feder AF. Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1012915
BibTeX
@article{Colegrove2025,
author = {Colegrove, Hunter L and Monnat, Raymond J and Feder, Alison F},
title = {Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1012915}
}
EUVIMED